Endpoint
Nocturnal voiding frequency (nocturia)
CAT:outcome/nocturnal-voiding-frequencyreported in voids per night2 findings from 1 compound
What moved it
How to read these marks2 findings · 1 compound · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| Serenoa repens | down | 2 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
Reported to move it
2 findings
Serenoa repens — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Pooled analysis of nine short-term Permixon trials found a significant reduction in the frequency of nocturia with a WMD of −0.79 times/night [95% CI −1.28 to −0.29], although there was evidence of profound heterogeneity (I2 76%).”
Quoted verbatim from Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.. - Study
- meta-analysis
- Population
- Nine short-term Permixon (Serenoa repens extract) trials vs placebo, men with LUTS consistent with BPH
Effect -0.79 mean difference, 95% CI -1.28 to -0.29
Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.2012PMID:22551330Permalink
Serenoa repens — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“Placebo was associated with a reduction in the mean number of nocturnal voids of 0.63 (0.14); there was a further reduction attributable to Permixon of 0.38 (0.07) (P < 0.001).”
Quoted verbatim from Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.. - Study
- meta-analysis
- Population
- Men with symptomatic BPH; pooled analysis of 14 randomized and 3 open-label Permixon trials (total N=4280) vs placebo
Effect 0.38 mean difference
Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.2004PMID:15049985Permalink
How it is measured
Number of nocturnal voids per night, counted from a voiding diary or patient report over a stated number of nights.
Sources cited
2 papers
- Subject
- nocturnal voiding frequency (nocturia)
- Findings
- 2
- Papers
- 2